This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignees: Fudan University, Shanghai Miracogen Inc, Chinese Academy of Sciences. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 224 
3 out of 5 
2 out of 3,346 
Years Active: 2020-2025
Title: Qing Lin: Innovator in Antibody-Drug Conjugates
Introduction
Qing Lin is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates (ADCs). With a total of 3 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Qing Lin's latest patents is a tissue factor-targeted antibody-drug conjugate. This ADC is designed to bind to tissue factor (TF) antigen with high specificity. It boasts high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity. This innovative approach has the potential to enhance the effectiveness of cancer therapies.
Career Highlights
Qing Lin has worked with notable institutions such as Fudan University and Shanghai Miracogen Inc. His experience in these organizations has allowed him to advance his research and contribute to the development of cutting-edge medical technologies.
Collaborations
Qing Lin has collaborated with several professionals in his field, including Ke Yu and Xuesai Zhang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Qing Lin's work in the development of antibody-drug conjugates represents a significant advancement in cancer treatment. His innovative patents and collaborations highlight his commitment to improving healthcare through biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile